Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2020

01-12-2020 | Multiple Sclerosis | Research article

Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis

Authors: Mina Mohammadhosayni, Arezou Khosrojerdi, Keivan Lorian, Saeed Aslani, Danyal Imani, Bahman Razi, Farhad Babaie, Shahram Torkamandi

Published in: BMC Neurology | Issue 1/2020

Login to get access

Abstract

Background

Several studies have reported the association between polymorphisms in Matrix metalloproteinases (MMPs) gene family and risk of Multiple sclerosis (MS). However, the results have been inconsistent and inconclusive. To resolve this issue, here we performed a systematic review and meta-analysis of the MMP-91562 C/T (rs3918242), MMP-3 (− 1612 5A/6A), and MMP-2 (− 1306 C/T) polymorphisms and susceptibility to MS.

Methods

We conducted a comprehensive systematic search in the major electronic database, including Scopus and PubMed to look up for relevant studies published before December 2019 that surveyed the association between the MMP-91562 C/T (rs3918242), MMP-3 (− 1612 5A/6A), and MMP-2 (− 1306 C/T) polymorphisms and susceptibility to MS. The level of association between the polymorphisms and susceptibility to MS in the polled analysis was determined by calculating the odds ratio (OR) and the corresponding 95% confidence interval (CI).

Results

We found 15 studies containing 2430 MS subjects and 2304 controls. A statistically significant association was observed in the all five comparisons of the MMP-91562 C/T polymorphism and MS risk as follows: dominant model (OR = 1.62, 95% CI = 1.03–2.53, P = 0.03), recessive model (OR = 2.69, 95% CI = 1.68–4.29, P < 0.001), allelic model (OR = 1.51, 95% CI = 1–2.28, P = 0.04), TT vs. CC model (OR = 3.20, 95% CI = 1.87–5.46, P < 0.001), and CT vs. CC model (OR = 1.53, 95% CI = 1.02–2.28, P = 0.04).

Conclusions

Our meta-analysis revealed significant association of MMP-9 (− 1562 C/T) Single-nucleotide polymorphism (SNP) with MS susceptibility that increased the disease risk.
Literature
1.
Imani D, et al. Association of nod-like receptor protein-3 single nucleotide gene polymorphisms and expression with the susceptibility to relapsing–remitting multiple sclerosis. Int J Immunogenet. 2018;45(6):329–36.PubMedCrossRef
2.
Campbell GR, Worrall JT, Mahad DJ. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult Scler J. 2014;20(14):1806–13.CrossRef
3.
4.
Kamińska J, et al. Multiple sclerosis-etiology and diagnostic potential. Postepy Hig Med Dosw (Online). 2017;71:551–63.CrossRef
5.
Emamnejad R, et al. Circulating mesenchymal stem cells, stromal derived factor (SDF)-1 and IP-10 levels increased in clinically active multiple sclerosis patients but not in clinically stable patients treated with beta interferon. Mult Scler Relat Disord. 2019;35:233–8.PubMedCrossRef
6.
Aslani S, et al. Epigenetic modifications and therapy in multiple sclerosis. NeuroMolecular Med. 2017;19(1):11–23.PubMedCrossRef
7.
Hawkes C, Macgregor A. Twin studies and the heritability of MS: a conclusion. Mult Scler J. 2009;15(6):661–7.CrossRef
8.
Kuusisto H, et al. Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins. Eur J Neurol. 2008;15(10):1106–10.PubMedCrossRef
9.
Fagnani C, et al. Twin studies in multiple sclerosis: a meta-estimation of heritability and environmentality. Mult Scler J. 2015;21(11):1404–13.CrossRef
10.
Vandenbroeck K, et al. High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease. Genes Immun. 2000;1(7):460.PubMedCrossRef
11.
Smolders J, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev. 2009;8(7):621–6.PubMedCrossRef
12.
Matesanz F, et al. Protein tyrosine phosphatase gene (PTPN22) polymorphism in multiple sclerosis. J Neurol. 2005;252(8):994–5.PubMedCrossRef
13.
14.
Yong VW, et al. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci. 2007;259(1–2):79–84.PubMedCrossRef
15.
Javan MR, et al. Downregulation of immunosuppressive molecules, PD-1 and PD-L1 but not PD-L2, in the patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 2016;15(4):296–302.PubMed
16.
Javan M-R, et al. Molecular analysis of interleukin-25 exons 1 and 2 and its serum levels in Iranian patients with multiple sclerosis. Am J Clin Exp Immunol. 2014;3(2):91.PubMedPubMedCentral
17.
Javan MR, et al. An interleukin 12 B single nucleotide polymorphism increases IL-12p40 production and is associated with increased disease susceptibility in patients with relapsing-remitting multiple sclerosis. Neurol Res. 2017;39(5):435–41.PubMedCrossRef
18.
Yoon S-O, et al. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003;36(1):128–37.PubMed
19.
Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998;10(5):602–8.PubMedCrossRef
20.
Chintala SK, Tonn JC, Rao JS. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci. 1999;17(5–6):495–502.PubMedCrossRef
21.
Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. In Progress in molecular biology and translational science. Vol. 147. Academic Press; 2017. p. 1–73.
22.
Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(sup1):177–83.PubMedCrossRef
23.
24.
Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19(7):623–9.PubMedCrossRef
25.
Kanamori Y, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999;59(17):4225–7.PubMed
26.
dos Reis ST, et al. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol. 2009;181(5):2320–5.PubMedCrossRef
27.
Mirowska-Guzel D, et al. Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a polish population. J Neuroimmunol. 2009;214(1–2):113–7.PubMedCrossRef
28.
Rahimi Z, et al. Functional promoter polymorphisms of MMP-2 C-735T and MMP-9 C-1562T and their synergism with MMP-7 A-181G in multiple sclerosis. Immunol Investig. 2016;45(6):543–52.CrossRef
29.
Nelissen I, et al. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol. 2000;105(1):58–63.PubMedCrossRef
30.
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRefPubMed
31.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
32.
Huedo-Medina TB, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193.PubMedCrossRef
33.
34.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
35.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef
36.
37.
Živković M, et al. Matrix metalloproteinase-9− 1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. J Neuroimmunol. 2007;189(1–2):147–50.PubMedCrossRef
38.
Benešová Y, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol. 2008;205(1–2):105–9.PubMedCrossRef
39.
La Russa A, et al. Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroimmunol. 2010;225(1–2):175–9.PubMedCrossRef
40.
Valado A, et al. Multiple sclerosis: association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease. Mult Scler Relat Disord. 2017;11:71–6.PubMedCrossRef
41.
Sabbagh S, et al. Association study between functional polymorphisms of MMP9 gene promoter and multiple sclerosis susceptibility in an Iranian population. Iran J Public Health. 2019;48(9):1697.PubMedPubMedCentral
42.
Sadr NKS, et al. Matrix Metalloproteinase-9 gene polymorphisms in south-west Iranian multiple sclerosis (MS) patients. Russ J Genet. 2019;55(10):1266–72.CrossRef
43.
Ibrahim I, et al. Matrix metalloproteases 9 rs3918242 gene polymorphism and serum vit D in MS Egyptian patients. Mult Scler Relat Disord. 2019;32:103–6.PubMedCrossRef
44.
Fernandes KS, et al. Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol. 2009;214(1–2):128–31.PubMedCrossRef
45.
Djurić T, et al. Association of the MMP-3 5A/6A gene polymorphism with multiple sclerosis in patients from Serbia. J Neurol Sci. 2008;267(1–2):62–5.PubMedCrossRef
46.
RAHIMI Z, ABBASI A, RAHIMI Z. Functional promoter polymorphism of matrix metalloproteinase (MMP)-3 5A/6A and its interaction with MMP-7 a-181G polymorphism in multiple sclerosis. Biharean Biologist. 2016;10(2):137–40.
47.
Liutkevičienė R, et al. Association of MMP-2 (−1306 C/T) gene polymorphism with predisposition to optic neuritis and optic neuritis together with multiple sclerosis. Medicina. 2018;54(2):29.PubMedCentralCrossRef
48.
Aksoy D, et al. Analysis of MMP2-1306C/T and TIMP2G-418C polymorphisms with relapsing remitting multiple sclerosis. J Investig Med. 2016;64(6):1143–7.PubMedCrossRef
49.
Nischwitz S, et al. MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene. J Neuroimmunol. 2015;279:46–9.PubMedCrossRef
50.
Li J, et al. Association study of MMP-9− 1562C/T gene polymorphism with susceptibility to multiple autoimmune diseases: a meta-analysis. Arch Med Res. 2017;48(1):105–12.PubMedCrossRef
51.
52.
Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5(8):2145–54.PubMedCrossRef
53.
Chandler S, et al. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett. 1995;201(3):223–6.PubMedCrossRef
54.
Gijbels K, et al. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res. 1993;36(4):432–40.PubMedCrossRef
55.
Proost P, Vandamme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun. 1993;192(3):1175–81.PubMedCrossRef
56.
Gijbels K, et al. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol. 1992;41(1):29–34.PubMedCrossRef
57.
Paemen L, et al. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol. 1994;1(1):55–63.PubMedCrossRef
58.
Benešová Y, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler J. 2009;15(3):316–22.CrossRef
59.
Shimajiri S, et al. Shortened microsatellite d (CA) 21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999;455(1–2):70–4.PubMedCrossRef
60.
Zhang B, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99(14):1788–94.PubMedCrossRef
61.
Zhang B, et al. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12. 2–13.1. Hum Genet. 1999;105(5):418–23.PubMed
Metadata
Title
Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis
Authors
Mina Mohammadhosayni
Arezou Khosrojerdi
Keivan Lorian
Saeed Aslani
Danyal Imani
Bahman Razi
Farhad Babaie
Shahram Torkamandi
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-020-01804-2

Other articles of this Issue 1/2020

BMC Neurology 1/2020 Go to the issue

Research article

Effect of anesthesia strategy during endovascular therapy on 90-day outcomes in acute basilar artery occlusion: a retrospective observational study

Research article

Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China

Research article

Chronically reduced IL-10 plasma levels are associated with hippocampal sclerosis in temporal lobe epilepsy patients

Research article

Severe pain-related adverse events of percutaneous dilatational tracheostomy performed by a neurointensivist compared with conventional surgical tracheostomy in neurocritically ill patients

Case report

Two case reports of distal upper limb weakness following influenza-like illness: an emerging pattern of para-infectious myositis in adults

Research article

Correlation of internal carotid artery diameter and carotid flow with asymmetry of the circle of Willis